NYSEAMERICAN:OCX - OncoCyte Stock Price, News & Analysis

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

OncoCyte Corp (NYSEAMERICAN:OCX) announced its earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.10). View OncoCyte's Earnings History.

OncoCyte is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for OncoCyte.

5 Wall Street analysts have issued twelve-month target prices for OncoCyte's stock. Their predictions range from $6.00 to $8.00. On average, they expect OncoCyte's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 215.3% from the stock's current price. View Analyst Price Targets for OncoCyte.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte.

Headlines about OCX stock have trended negative on Thursday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OncoCyte earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for OncoCyte.

OncoCyte saw a decline in short interest in the month of August. As of August 15th, there was short interest totalling 1,007,700 shares, a decline of 18.8% from the July 15th total of 1,240,400 shares. Based on an average trading volume of 365,900 shares, the days-to-cover ratio is presently 2.8 days. Approximately 3.3% of the shares of the stock are sold short. View OncoCyte's Current Options Chain.

Some companies that are related to OncoCyte include Paradigm Biopharmaceuticals (PAR), ProMetic Life Sciences (PLI), Rafael (RFL), CEL-SCI (CVM), Pfenex (PFNX), 22nd Century Group (XXII), Emblem (EMC), Acasti Pharma (ACST), Emerald Health Therapeutics (EMH), Monash IVF Group (MVF), Senesco Technologies (ELOX), Horizon Discovery Group (HZD), Botanix Pharmaceuticals (BOT), Neuren Pharmaceuticals (NEU) and Enochian Biosciences (ENOB).

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include BioTime (BTX), Alnylam Pharmaceuticals (ALNY), Novocure (NVCR), Alibaba Group (BABA), Geron (GERN), Asterias Biotherapeutics (AST), Anavex Life Sciences (AVXL), Progenics Pharmaceuticals (PGNX), Apricus Biosciences (APRI) and AVEO Pharmaceuticals (AVEO).

OncoCyte's stock is owned by a number of of retail and institutional investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (4.58%), BlackRock Inc. (2.99%), Vanguard Group Inc. (2.72%), Maven Securities LTD (0.41%), Bank of New York Mellon Corp (0.15%) and Northern Trust Corp (0.14%). Company insiders that own OncoCyte stock include Biotime Inc, Broadwood Partners, LP and Mitchell S Levine. View Institutional Ownership Trends for OncoCyte.

OCX stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust and Morgan Stanley. View Insider Buying and Selling for OncoCyte.

OCX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Maven Securities LTD, Vanguard Group Inc., Jane Street Group LLC, Bank of New York Mellon Corp, Doheny Asset Management CA, Charles Schwab Investment Management Inc. and Wells Fargo & Company MN. Company insiders that have bought OncoCyte stock in the last two years include Broadwood Partners, LP and Mitchell S Levine. View Insider Buying and Selling for OncoCyte.

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OCX stock can currently be purchased for approximately $2.22.

OncoCyte has a market capitalization of $115.37 million. OncoCyte employs 12 workers across the globe.View Additional Information About OncoCyte.

The official website for OncoCyte is http://www.oncocyte.com/.

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.